Thermi Treatments
Indication and Safety Information
Find a Thermi Doctor

Author Archive for: trs_thermi

Thermi Receives Notice Of Complete And Satisfactory Closure Of FDA’s “Vaginal Rejuvenation” Inquiry

trs_thermi, August 22, 2019August 22, 2019, News, 0

IRVING, Texas, Nov. 15, 2018 /PRNewswire/ -- Thermi®, an Almirall, S.A. company, today announced that it has received a notice of completion...

3 likes Read more

Thermi®‘s temperature controlled RF system is indicated:

• In the United States for use in dermatological and general surgical procedures for electrocoagulation and hemostasis.
• In Europe for electrocoagulation of soft tissues for vulvovaginal laxity.

Important Safety Considerations:
Thermi radiofrequency products should not be used on patients who are pregnant, have a fever or skin infection in or around the area of treatment. Expected procedure side effects may include transient pain in the procedure area, erythema and edema.

Individual results may vary. Models not actual patients.
© 2020 ThermiGen, LLC. All rights reserved.

The ARVATI device is intended to create lesions in nervous tissue and for use in dermatological and general surgical procedures for electrocoagulation and hemostasis.

More Information:

THERMIva®
THERMItight®
THERMIsmooth®
THERMIrase ®

Compare THERMIva® to Plastic Surgery, Cosmetic Surgery, Mommy Makeovers, Vaginoplasty or Labiaplasty and Mini Tummy Tucks.

Find a Thermi Provider

For Physicians

Thermi

4719 South Congress Avenue
Austin, TX 78745

Phone: (512) 637-6745
Fax: (214)-279-0101
Email: orders@thermi.com

This site is intended for US use.

Log in with your credentials

Remember me Lost your password?

Forgot your details?

I remember my details

Thermi Receives Notice Of Complete And Satisfactory Closure Of FDA’s “Vaginal Rejuvenation” Inquiry

Recent Posts

Recent Comments

Archives

Categories

Meta